Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis
Phase meta-analysisN = 11,151
- Population
- Patients with AML in 81 publications (11,151 patients); studies reporting only outcomes after hematopoietic cell transplantation were excluded.
- Design
- Systematic review (PubMed, Embase, MEDLINE; studies published January 2000 to October 2018) with Bayesian hierarchical meta-analysis of survival probabilities and hazard ratios by MRD status for disease-free and overall survival. 81 publications.
- Arms
- MRD negative (experimental): Achieved MRD negativity
- MRD positive (control): MRD present
- People
- Short NJ
OSHR 0.36Δ 60-month OS+34 pointsDFSHR 0.37Δ 60-month DFS+39 points
Show the numbers
| Endpoint | Analysis | MRD negative | MRD positive | Effect |
|---|---|---|---|---|
| OSAll pooled studies (81 publications) | primaryShort 2020 | 68% at 5 y | 34% at 5 y | HR 0.36Hazard ratio for achieving MRD negativity; the interval published is a 95% Bayesian credible interval of 0.33 to 0.39. The abstract gives the estimated overall survival (68% without MRD, 34% with MRD) in the same sentence as the 5-year disease-free survival; the open full text states the 5-year estimates for OS as 68% (95% CrI 63-73) and 34% (28-40). |
| DFSAll pooled studies (81 publications) | primaryShort 2020 | 64% at 5 y | 25% at 5 y | HR 0.37Hazard ratio for achieving MRD negativity; the interval published is a 95% Bayesian credible interval of 0.34 to 0.40. |
| Endpoint | Analysis | MRD negative | MRD positive | Effect |
|---|---|---|---|---|
| OSAll pooled studies (81 publications) | primaryShort 2020 | 68% at 5 y | 34% at 5 y | HR 0.36Hazard ratio for achieving MRD negativity; the interval published is a 95% Bayesian credible interval of 0.33 to 0.39. The abstract gives the estimated overall survival (68% without MRD, 34% with MRD) in the same sentence as the 5-year disease-free survival; the open full text states the 5-year estimates for OS as 68% (95% CrI 63-73) and 34% (28-40). |
| DFSAll pooled studies (81 publications) | primaryShort 2020 | 64% at 5 y | 25% at 5 y | HR 0.37Hazard ratio for achieving MRD negativity; the interval published is a 95% Bayesian credible interval of 0.34 to 0.40. |